Targeted Naltrexone: A New Hope for Binge Drinking in Minority Men
Targeted naltrexone significantly reduced drinking outcomes among sexual and gender minority men with mild to moderate alcohol use disorder during treatment, with sustained effects at six months post-treatment.
Ever thought about how binge drinking could be tackled more effectively? In this episode of the 'Addiction Medicine Journal Club', Drs. Sonya Del Tredici and John Keenan take a closer look at a groundbreaking study on targeted oral naltrexone for mild to moderate alcohol use disorder among sexual and gender minority men. This randomized trial offers some eye-opening results, showing that targeted naltrexone can significantly reduce binge drinking episodes and maintain these positive effects for up to six months post-treatment.
The hosts also explore alternative dosing strategies, potential side effects, and the broader implications for addiction medicine practice. To make things even more relatable, they share a patient case study that brings the trial's findings to life. Plus, they touch on the recent drop in overdose deaths in the United States and California's ambitious plans to phase out smoking. It's an episode packed with valuable insights and practical takeaways that you won't want to miss.